Systemic Lupus Erythematosus: A Therapeutic Update
Identifieur interne : 001810 ( Main/Exploration ); précédent : 001809; suivant : 001811Systemic Lupus Erythematosus: A Therapeutic Update
Auteurs : Catherine A. Heyneman [États-Unis]Source :
- Journal of Pharmacy Practice [ 0897-1900 ] ; 2009-02.
English descriptors
- Teeft :
- Antimalarial, Antinuclear, Antiphospholipid, Arthritis, Arthritis rheum, Atherosclerosis, Autoantibody, Autoantibody production, Azathioprine, Cardiovascular, Cardiovascular disease, Chloroquine, Clin, Clinical trials, Concomitant, Corticosteroid, Cutaneous, Cyclophosphamide, Cytokine, Cytotoxic, Disease activity, Erythematosus, Etanercept, February, Heyneman, Humanized, Hydroxychloroquine, Hypertension, Immune, Immunoglobulin, Immunosuppressive, Infliximab, Infusion, Intravenous, Intravenous immunoglobulin, Ivig, Lupus, Lupus erythematosus, Lupus nephritis, Lymphocyte, Methotrexate, Methylprednisolone, Mofetil, Morbidity, Mycophenolate, Mycophenolate mofetil, Nephritis, Nsaid, Pathogenesis, Pharmacy practice, Placebo, Plasmapheresis, Proliferative, Proteinuria, Randomized, Receptor, Remission, Rheum, Rheumatoid, Rheumatoid arthritis, Rheumatol, Rituximab, Systemic, Systemic lupus erythematosus.
Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical manifestations that is characterized by flares and periods of relative quiescence. The disease occurs approximately 10 times more frequently in women and is more prevalent among certain ethnic groups. The etiology is complex and dependent upon an interaction of genetic, hormonal, and environmental factors. Corticosteroids and immunosuppressive agents have transformed the outlook for patients with lupus. Unfortunately, the increased lifespan unmasked an accelerated process of atherosclerosis and cardiovascular disease. Early mortality is usually attributable to active lupus, but deaths late in the disease process are often secondary to thrombotic events. Advancements in the understanding of molecular and cellular mechanisms involved in the pathogenesis have resulted in development of novel therapies. Immunomodulatory drugs developed for other diseases are being investigated for use in specific manifestations of lupus. Individualization of treatment and lifelong monitoring are required in most patients.
Url:
DOI: 10.1177/0897190008322246
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000088
- to stream Istex, to step Curation: 000088
- to stream Istex, to step Checkpoint: 000735
- to stream Main, to step Merge: 001814
- to stream Main, to step Curation: 001810
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Systemic Lupus Erythematosus: A Therapeutic Update</title><author wicri:is="90%"><name sortKey="Heyneman, Catherine A" sort="Heyneman, Catherine A" uniqKey="Heyneman C" first="Catherine A." last="Heyneman">Catherine A. Heyneman</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F9A18FD1D0D02C49BA364F8998F0ED79C450C89B</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1177/0897190008322246</idno><idno type="url">https://api.istex.fr/ark:/67375/M70-TWGHMBM4-B/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000088</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000088</idno><idno type="wicri:Area/Istex/Curation">000088</idno><idno type="wicri:Area/Istex/Checkpoint">000735</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000735</idno><idno type="wicri:doubleKey">0897-1900:2009:Heyneman C:systemic:lupus:erythematosus</idno><idno type="wicri:Area/Main/Merge">001814</idno><idno type="wicri:Area/Main/Curation">001810</idno><idno type="wicri:Area/Main/Exploration">001810</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Systemic Lupus Erythematosus: A Therapeutic Update</title><author wicri:is="90%"><name sortKey="Heyneman, Catherine A" sort="Heyneman, Catherine A" uniqKey="Heyneman C" first="Catherine A." last="Heyneman">Catherine A. Heyneman</name><affiliation></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of Pharmacy Practice</title><idno type="ISSN">0897-1900</idno><idno type="eISSN">1531-1937</idno><imprint><publisher>SAGE Publications</publisher><pubPlace>Sage CA: Los Angeles, CA</pubPlace><date type="published" when="2009-02">2009-02</date><biblScope unit="volume">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="29">29</biblScope><biblScope unit="page" to="52">52</biblScope></imprint><idno type="ISSN">0897-1900</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0897-1900</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Antimalarial</term><term>Antinuclear</term><term>Antiphospholipid</term><term>Arthritis</term><term>Arthritis rheum</term><term>Atherosclerosis</term><term>Autoantibody</term><term>Autoantibody production</term><term>Azathioprine</term><term>Cardiovascular</term><term>Cardiovascular disease</term><term>Chloroquine</term><term>Clin</term><term>Clinical trials</term><term>Concomitant</term><term>Corticosteroid</term><term>Cutaneous</term><term>Cyclophosphamide</term><term>Cytokine</term><term>Cytotoxic</term><term>Disease activity</term><term>Erythematosus</term><term>Etanercept</term><term>February</term><term>Heyneman</term><term>Humanized</term><term>Hydroxychloroquine</term><term>Hypertension</term><term>Immune</term><term>Immunoglobulin</term><term>Immunosuppressive</term><term>Infliximab</term><term>Infusion</term><term>Intravenous</term><term>Intravenous immunoglobulin</term><term>Ivig</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus nephritis</term><term>Lymphocyte</term><term>Methotrexate</term><term>Methylprednisolone</term><term>Mofetil</term><term>Morbidity</term><term>Mycophenolate</term><term>Mycophenolate mofetil</term><term>Nephritis</term><term>Nsaid</term><term>Pathogenesis</term><term>Pharmacy practice</term><term>Placebo</term><term>Plasmapheresis</term><term>Proliferative</term><term>Proteinuria</term><term>Randomized</term><term>Receptor</term><term>Remission</term><term>Rheum</term><term>Rheumatoid</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rituximab</term><term>Systemic</term><term>Systemic lupus erythematosus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Systemic lupus erythematosus (SLE) is a complex autoimmune disease with variable clinical manifestations that is characterized by flares and periods of relative quiescence. The disease occurs approximately 10 times more frequently in women and is more prevalent among certain ethnic groups. The etiology is complex and dependent upon an interaction of genetic, hormonal, and environmental factors. Corticosteroids and immunosuppressive agents have transformed the outlook for patients with lupus. Unfortunately, the increased lifespan unmasked an accelerated process of atherosclerosis and cardiovascular disease. Early mortality is usually attributable to active lupus, but deaths late in the disease process are often secondary to thrombotic events. Advancements in the understanding of molecular and cellular mechanisms involved in the pathogenesis have resulted in development of novel therapies. Immunomodulatory drugs developed for other diseases are being investigated for use in specific manifestations of lupus. Individualization of treatment and lifelong monitoring are required in most patients.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Heyneman, Catherine A" sort="Heyneman, Catherine A" uniqKey="Heyneman C" first="Catherine A." last="Heyneman">Catherine A. Heyneman</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001810 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001810 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F9A18FD1D0D02C49BA364F8998F0ED79C450C89B
|texte= Systemic Lupus Erythematosus: A Therapeutic Update
}}
| This area was generated with Dilib version V0.6.33. |  |